보고서 요약(국문)

개요
전 세계 안지오텐신 전환 효소 억제제(ACE 억제제) 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
ACE 억제제는 심혈관 질환, 신장 질환, 당뇨병 등을 치료하는 데 사용되는 약물 계열입니다. 다른 약물과 병용하여 고혈압을 치료하는 데 사용되며, 미국 식품의약국(FDA) 승인을 받은 용도에는 수축기 심부전의 보조 요법이 포함됩니다. 또한 심근 감염 치료에도 사용됩니다.
작용 기전은 안지오텐신 전환 효소를 차단하여 혈압을 낮추는 것입니다. 고혈압 치료 외에도, 이러한 억제제는 신증후군, 사구체 감염 및 기타 신장 염증과 같은 여러 신장 질환을 치료합니다. 리시노프릴과 베나제프릴은 대표적인 ACE 억제제입니다.

시장 동향: 성장 동력 및 제약 요인
심혈관 질환의 증가
심혈관 질환은 전 세계적으로 주요 사망 원인 중 하나입니다. 세계보건기구(WHO)에 따르면 2023년 기준 매년 약 1,700만 명이 심혈관 질환, 특히 뇌졸중과 심장마비로 사망합니다. 심혈관 질환은 남녀 모두에게 동일하게 발생하며, 건강하지 못한 식습관과 당뇨병, 고혈압 등의 기저 질환이 많은 사람들에게 심장마비의 원인이 됩니다.
또한, 영국 심장 재단(British Heart Foundation)에 따르면 2023년 기준 약 6억 2천만 명이 심장 질환을 앓고 있습니다. 전 세계적으로 13명 중 1명꼴로 심장 또는 순환기 질환을 앓고 있는 것으로 추정됩니다. 매년 6천만 명 이상이 심장 질환에 걸리는데, 이는 영국 인구와 거의 같은 수치입니다.
2023년 3월, 하버드 경영대학원(Harvard Business School)의 연구에 따르면 젊은 성인층에서 당뇨병 및 고혈압과 함께 심혈관 질환 위험이 증가하는 것으로 나타났습니다.

ACE 억제제 치료의 부작용
ACE 억제제는 고혈압 치료에 사용되지만, 다른 항고혈압제와 병용 투여 시 저혈압을 유발할 수 있습니다. ACE 억제제를 과다 복용하면 고칼륨혈증(혈중 칼륨 수치 상승)이 발생할 수 있습니다. 드물지만 생명을 위협하는 부작용으로 혈관부종이 발생할 수 있습니다. 심부전 및 신장 관류 저하 환자의 경우 ACE 억제제 치료 시 사구체 여과율이 더욱 감소할 수 있습니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 안지오텐신 전환 효소 억제제(ACE 억제제) 시장은 약물 유형, 적용 분야, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
디카르복실산 함유 제제 부문은 시장 점유율의 약 47.1%를 차지했습니다.
디카르복실산 함유 ACE 억제제는 향후 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. ACE 억제제는 심혈관계, 폐, 신장 질환 등과 같은 질환 치료를 위한 임상 시험 단계에 있습니다. ACE 억제제를 포함하는 병용 요법은 심장 질환 및 기타 질환을 앓고 있는 환자에게 투여됩니다.
2023년 9월, 파마사이언스(Pharmascience Inc.)는 모든 연령대의 고혈압 환자의 혈압을 낮추기 위해 안지오텐신 전환 효소(ACE) 억제제와 이뇨제를 결합한 페린도프릴-인다파미드 복합제를 출시했습니다.
인도 만성 질환 관리 센터(Centre for Chronic Disease Control, India)는 임페리얼 칼리지 런던(Imperial College London) 및 인도 전역 의학 연구소(All India Institute of Medical Sciences, New Delhi)와 함께 두 가지 항고혈압제인 암로디핀과 페린도프릴의 세 가지 단일 정제 복합제의 효능을 비교하는 4상 임상 시험을 진행하고 있습니다. 본 연구의 시작일은 2022년 8월 30일이며, 예상 완료일은 2023년 12월 31일입니다.
지역 분석
북미는 2022년 시장 점유율의 약 39.6%를 차지했습니다.
미국과 캐나다의 당뇨병 유병률로 인해 북미는 앞으로도 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. ACE 억제제는 체내 안지오텐신 효소를 차단하는 효능 덕분에 당뇨병, 고혈압 등을 치료하는 데 사용됩니다.
예를 들어, 범미보건기구(PAHO)에 따르면 미주 지역에는 6,200만 명의 당뇨병 환자가 있으며, 무증상 환자가 약 40%에 달하는 점을 고려하면 실제 환자 수는 훨씬 더 많을 것으로 예상됩니다. 당뇨병은 미국에서 여섯 번째로 흔한 사망 원인이며, 2019년에는 28만 4천 명 이상이 당뇨병으로 사망했습니다. 미국에서는 건강하지 못한 식습관과 좌식 생활 방식으로 인해 제2형 당뇨병 유병률이 급격히 증가하고 있습니다.

USC 셰퍼 건강 정책 및 경제 센터에 따르면, 2023년에는 미국인의 약 70%가 평생 동안 고혈압을 경험할 것으로 예상됩니다. 고혈압 환자 4명 중 1명만이 혈압을 조절하고 있으며, 나머지는 무증상입니다.
코로나19 영향 분석
코로나19는 안지오텐신 효소 억제제(ACE 억제제) 시장에 중간 정도의 영향을 미쳤습니다. 팬데믹 기간 동안 공급망 차질이 발생했습니다. 코로나19 감염자는 주로 당뇨병, 고혈압, 심장 질환과 같은 기저 질환을 가지고 있습니다. 심장 질환 환자의 약물 복용이 중단되지 않았기 때문에 ACE 억제제 시장에 미치는 영향은 크지 않았습니다. 전 세계적인 봉쇄 조치로 인해 감염에 대한 두려움 때문에 심혈관 질환 검사 및 진단이 어려워졌습니다.

경쟁 환경
안지오텐신 전환 효소 억제제(ACE 억제제) 시장의 주요 글로벌 업체로는 Camber Pharmaceuticals, Inc., Pfizer Inc, Merck & Co., Inc, Biogaran, Lupin Pharmaceuticals, Inc., Crescent Pharma Limited, Global Pharma Pvt Ltd, SCHWITZ BIOTECH, Steris Healthcare PVT Ltd, Auro Pharma Inc 등이 있습니다.
주요 개발 사항
• 2021년 2월, Novartis는 만성 심부전 치료제 Entresto에 대해 미국 식품의약국(FDA)의 승인을 받았습니다.

• 2021년 1월, Merck & Co, Inc.는 심부전으로 입원 치료를 받은 환자를 위한 만성 심부전 치료제 VERQUVO에 대해 미국 FDA의 승인을 받았습니다. 이 약은 Bayer AG와 공동 개발되었습니다.
보고서 구매 이유

• 약물 유형, 적용 분야, 투여 경로, 유통 채널 및 지역별 글로벌 안지오텐신 전환 효소 억제제(ACE 억제제) 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 ACE 억제제 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 ACE 억제제(ACE 억제제) 시장 보고서는 약 69개의 표, 70개의 그림, 195페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Angiotensin-Converting Enzyme Inhibitors (ACE) Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
ACE inhibitors are a class of medication used for treating cardiovascular diseases, renal diseases, diabetes mellitus, etc. They are used to treat hypertension in combination with other drugs. The FDA-approved uses include adjunctive therapy in systolic heart failure. It is also used for myocardial infection.
The mechanism of action involves the blockage of the angiotensin-converting enzyme that lowers the blood pressure. Besides treating hypertension, these inhibitors treat several kidney diseases like nephrotic syndrome, glomerular infections, and other kidney inflammations. Lisinopril and benazepril are famous examples of ACE inhibitors.
Market Dynamics: Drivers & Restraints
Increasing prevalence of cardiovascular diseases
Cardiovascular diseases are one of the leading causes of death around the world. According to the World Health Organisation, 2023, an estimated 17 million people die annually due to cardiovascular diseases, mainly stroke and heart attacks. It affects men and women equally due to unhealthy diet habits and underlying health ailments like diabetes, hypertension, etc, which lead to heart strokes in many individuals.
Furthermore, according to the British Heart Foundation, 2023, nearly 620 million people live with cardiac diseases. Globally, it is estimated that 1 in 13 individuals currently suffer from heart or circulatory disease. Each year, more than 60 million people develop cardiac diseases, which are almost the same as the population of the UK.
In March 2023, according to Harvard Business School 2023, the study revealed an increased risk of cardiovascular diseases along with diabetes and hypertension among young adults.
Side effects of ACE inhibitor therapy
ACE inhibitors are used to treat hypertension, but sometimes, when given with other anti-hypertensive agents, it leads to hypotension. Excessive usage of ACE inhibitors leads to hyperkalemia, where increased potassium levels are seen. Adverse drug reaction is possible, leading to angioedema, a rare but life-threatening situation. Patients with heart failure and poor renal perfusion lead to further reduction of glomerular filtration rate with ACE inhibitor therapy.
For more details on this report – Request for Sample
Segment Analysis
The global angiotensin-converting enzyme inhibitors (ACE) are segmented based on drug type, application, route of administration, distribution channel, and region.
The Dicarboxylic-containing agents segment accounted for approximately 47.1% of the market share
Dicarboxylic-containing ACE inhibitors are expected to hold the largest share of the market. ACE inhibitors are under clinical trial for treating diseases like cardiovascular, lung, renal, etc. A combination therapy containing ACE inhibitors is given to patients suffering from cardiac ailments and other diseases.
In September 2023, Pharmascience Inc. launched PERINDOPRIL-INDAPAMIDE, a combination of an angiotensin-converting enzyme (ACE) inhibitor and diuretic to lower blood pressure in hypertensive patients of all ages.
The Centre for Chronic Disease Control, India, along with Imperial College London, All India Institute of Medical Sciences, New Delhi, is conducting phase 4 clinical trials to compare the efficacy of three single-pill combinations of two anti-hypertensive agents, Amlodipine and Perindopril. The study start date is August 30, 2022. The estimated completion date is December 31, 2023.
Geographical Analysis
North America accounted for approximately 39.6% of the market share in 2022
North America is expected to hold the largest market share due to the prevalence of diabetes mellitus in the US and Canada. ACE inhibitors are used to treat diabetes mellitus, hypertension, etc., due to their efficacy in blocking the angiotensin enzyme in the body.
For instance, according to the Pan American Health Organization, 62 million people live with diabetes in the Americas, which is expected to be much higher given that around 40% of those without any symptoms. Diabetes is America's sixth leading cause of mortality and was responsible for over 284,000 deaths in 2019. The prevalence of type 2 diabetes is increasing drastically due to unhealthy food habits and sedentary lifestyles in America.
According to the USC Schaeffer Center for Health Policy & Economics, in 2023, about 70% of Americans will have high blood pressure in their lifetimes. Only 1 in 4 patients with hypertension were in control, and others are asymptomatic.
COVID-19 Impact Analysis
Covid 19 moderately impacted the angiotensin enzyme inhibitor market. Disruption in the supply chain was observed during the pandemic. People who contracted COVID-19 mainly have underlying co-morbidities like diabetes, hypertension, and heart ailments. As there is no termination in the drug intake by people suffering from heart ailments, there is not much impact observed on ACE inhibitors market. The implementation of lockdowns worldwide made testing and diagnosing cardiovascular diseases difficult because there is a high fear of contracting the disease.
Competitive Landscape
The major global players in the angiotensin-converting enzyme inhibitors (ACE) market include Camber Pharmaceuticals, Inc., Pfizer Inc, Merck & Co., Inc, Biogaran, Lupin Pharmaceuticals, Inc., Crescent Pharma Limited, Global Pharma Pvt Ltd, SCHWITZ BIOTECH, Steris Healthcare PVT Ltd, Auro Pharma Inc among others.
Key Developments
• In February 2021, Novartis received US Food and Drug Administration approval for Entresto for the treatment of chronic heart failure.
• In January 2021, Merck & Co, Inc., received US Food and Drug Administration approval for VERQUVO for the treatment of chronic heart failure specifically approved for patients following a hospitalization for heart failure. It is jointly developed with Bayer AG.
Why Purchase the Report?
• To visualize the global angiotensin-converting enzyme inhibitors market segmentation based on drug type, application, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of angiotensin-converting enzyme inhibitors market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global angiotensin-converting enzyme inhibitors (ACE) market report would provide approximately 69 tables, 70 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Application
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Increasing prevalence of cardiovascular diseases
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Side effects of ACE inhibitor therapy
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Cardiovascular disease statistics
5.5. Regulatory Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Dicarboxylate-containing Agents *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Enalapril
7.2.2.2. Ramipril
7.2.2.3. Quinapril
7.2.2.4. Others
7.3. Phosphonate-containing Agents
7.3.1. Fosinopril
7.3.2. Others
7.4. Sulfhydryl-containing Agents
7.4.1. Alacepril
7.4.2. Captopril
7.4.3. Others
7.5. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Cardiovascular Diseases*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Renal Diseases
8.4. Diabetes
8.5. Hypertension
8.6. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Camber Pharmaceuticals, Inc.
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Pfizer Inc
13.3. Merck & Co., Inc
13.4. Biogaran
13.5. Lupin Pharmaceuticals, Inc.
13.6. Crescent Pharma Limited
13.7. Global Pharma Pvt Ltd
13.8. SCHWITZ BIOTECH
13.9. Steris Healthcare PVT Ltd
13.10. Auro Pharma Inc
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Camber Pharmaceuticals, Inc., 4. Key Developments, Pfizer Inc, Merck & Co., Inc, Biogaran, Lupin Pharmaceuticals, Inc., Crescent Pharma Limited, Global Pharma Pvt Ltd, SCHWITZ BIOTECH, Steris Healthcare PVT Ltd, Auro Pharma Inc

표 목록 (Tables)

List of Tables

Table 1 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 8 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Application, 2022-2031 (US$ Million)

Table 10 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 12 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 14 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 17 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Application, 2022-2031 (US$ Million)

Table 18 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 22 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Application, 2022-2031 (US$ Million)

Table 23 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 24 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 25 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 27 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Application, 2022-2031 (US$ Million)

Table 28 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 29 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 30 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Application, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East & Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 37 Middle East & Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Application, 2022-2031 (US$ Million)

Table 38 Middle East & Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 39 Middle East & Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 40 Camber Pharmaceuticals, Inc.: Overview

Table 41 Camber Pharmaceuticals, Inc.: Product Portfolio

Table 42 Camber Pharmaceuticals, Inc.: Key Developments

Table 43 Pfizer Inc: Overview

Table 44 Pfizer Inc: Product Portfolio

Table 45 Pfizer Inc: Key Developments

Table 46 Merck & Co., Inc: Overview

Table 47 Merck & Co., Inc: Product Portfolio

Table 48 Merck & Co., Inc: Key Developments

Table 49 Biogaran: Overview

Table 50 Biogaran: Product Portfolio

Table 51 Biogaran: Key Developments

Table 52 Lupin Pharmaceuticals, Inc.: Overview

Table 53 Lupin Pharmaceuticals, Inc.: Product Portfolio

Table 54 Lupin Pharmaceuticals, Inc.: Key Developments

Table 55 Crescent Pharma Limited: Overview

Table 56 Crescent Pharma Limited: Product Portfolio

Table 57 Crescent Pharma Limited: Key Developments

Table 58 Global Pharma Pvt Ltd: Overview

Table 59 Global Pharma Pvt Ltd: Product Portfolio

Table 60 Global Pharma Pvt Ltd: Key Developments

Table 61 SCHWITZ BIOTECH: Overview

Table 62 SCHWITZ BIOTECH: Product Portfolio

Table 63 SCHWITZ BIOTECH: Key Developments

Table 64 Steris Healthcare PVT Ltd: Overview

Table 65 Steris Healthcare PVT Ltd: Product Portfolio

Table 66 Steris Healthcare PVT Ltd: Key Developments

Table 67 Auro Pharma Inc: Overview

Table 68 Auro Pharma Inc: Product Portfolio

Table 69 Auro Pharma Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 2 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Drug Type, 2022 & 2031 (%)

Figure 3 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Application, 2022 & 2031 (%)

Figure 4 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 5 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 6 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 8 Dicarboxylate-containing Agents Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 9 Phosphonate-containing Agents Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 10 Sulfhydryl-containing Agents Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 11 Others Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 12 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 13 Cardiovascular Diseases Application in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 14 Renal Diseases Application in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 15 Diabetes Application in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 16 Hypertension Application in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 17 Others Application in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 18 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 19 Oral Route of Administration in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 20 Parenteral Route of Administration in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 21 Others Route of Administration in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 22 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 23 Hospital Pharmacies in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 24 Online Pharmacies in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 25 Retail Pharmacies in Global Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 26 Global Angiotensin-converting enzyme Inhibitors (ACE)Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 27 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 28 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 29 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 30 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 31 Middle East and Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 32 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 33 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Drug Type, 2022 & 2031 (%)

Figure 34 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Application, 2022 & 2031 (%)

Figure 35 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 36 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 37 North America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Country, 2022 & 2031 (%)

Figure 38 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 39 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Drug Type, 2022 & 2031 (%)

Figure 40 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Application, 2022 & 2031 (%)

Figure 41 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 42 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 43 South America Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Country, 2022 & 2031 (%)

Figure 44 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 45 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Drug Type, 2022 & 2031 (%)

Figure 46 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Application, 2022 & 2031 (%)

Figure 47 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 48 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 49 Europe Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Country, 2022 & 2031 (%)

Figure 50 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 51 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Drug Type, 2022 & 2031 (%)

Figure 52 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Application, 2022 & 2031 (%)

Figure 53 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 54 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 55 Asia-Pacific Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Country, 2022 & 2031 (%)

Figure 56 Middle East & Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Value, 2022-2031 (US$ Million)

Figure 57 Middle East & Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Drug Type, 2022 & 2031 (%)

Figure 58 Middle East & Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Application, 2022 & 2031 (%)

Figure 59 Middle East & Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 60 Middle East & Africa Angiotensin-converting enzyme Inhibitors (ACE)Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 61 Camber Pharmaceuticals, Inc.: Financials

Figure 62 Pfizer Inc: Financials

Figure 63 Merck & Co., Inc: Financials

Figure 64 Biogaran: Financials

Figure 65 Lupin Pharmaceuticals, Inc.: Financials

Figure 66 Crescent Pharma Limited: Financials

Figure 67 Global Pharma Pvt Ltd: Financials

Figure 68 SCHWITZ BIOTECH: Financials

Figure 69 Steris Healthcare PVT Ltd: Financials

Figure 70 Auro Pharma Inc: Financials

글로벌 안지오텐신 전환 효소 억제제(ACE) 시장 – 2023-2030

Global Angiotensin-Converting Enzyme Inhibitors (ACE) Market - 2023-2030